



Flash BioSolutions increases Gene Delivery RUO production capacity in France to meet surging demand for C2 and C3 GMO-Level Viral Particles

Toulouse, Occitanie, France, September 23, 2024 – Flash BioSolutions, a leading CDMO specializing in gene delivery, announces a significant expansion of its research-use-only (RUO) bioproduction capabilities to meet the growing demand for projects requiring containment levels 2 and 3 for GMOs (C2 and C3). This strategic initiative, set to be operational by October 2024, doubles the company's RUO production capacity and reinforces Flash BioSolutions' position as a premier global partner in the cell and gene therapy sector.

The expansion complements Flash BioSolutions' existing GMP and RUO capacities, enabling the company to deliver 1000+ lentiviral constructions per year. This is in addition to the impressive 11,000 constructions performed over the past 20 years, showcasing the company's extensive experience and reliability in the field.

Dr. Christine Duthoit, Chief Scientific Officer at Flash BioSolutions, highlights the significance of this expansion: "Our RUO lentiviruses play a key role in several promising pharmaceutical developments in gene therapy and cancer immunotherapy. They are essential for CAR and TCR research and the development of therapeutic vaccines. In research, these lentiviruses are invaluable tools for creating stable cell lines and studying gene function. They also aid in developing animal models. Additionally, in regenerative medicine, we are exploring approaches that use RNA vectors for reprogramming and differentiation purposes."

Leveraging its strategic location in France, Flash BioSolutions offers unparalleled expertise and a distinct advantage in serving European and North American markets, enhancing responsiveness and significantly reducing delivery times.

"This expansion underscores our ambition to support the exponential growth of gene and cell therapies across Europe and North America," states Jérôme Bédier, CEO of Flash BioSolutions. "Our strategic position in France, combined with our enhanced capabilities, enables us to provide crucial support to clients worldwide, addressing the challenges of a rapidly evolving international market. We are fully prepared to make a transformative contribution to the advancement of regenerative medicine and vaccination on a truly global scale."

About Flash BioSolutions:

Flash BioSolutions® is a preeminent CDMO specializing in the industrial-scale production of DNA and RNA vectors for clientele within the domains of gene and cell therapy, and vaccine development. Bolstered by a robust manufacturing platform and validated processes honed over two decades, Flash BioSolutions® excels in delivering vectors of unmatched purity and concentration across research, pre-clinical, and clinical phases.

Contact:

Head of communication

Soraya Sandokchi

+33 582 955 546

soraya.sandokchi@flashbiosolutions.com